Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
EERP initiates coverage of Virtualware (ALVIR) with a BUY rating and a €7.42 target price.
-
FORM 8.5 (EPT/RI) Amendment 2(a) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the...
-
CALGARY, Alberta, June 22, 2026 (GLOBE NEWSWIRE) -- Atlas Energy Corp. (“Atlas” or the “Company”) (TSXV: ATLE), a TSXV Sandbox issuer, is pleased to announce that Patrick Drouin and Dion Degrand...
-
Sparklight Strengthens Local Communities through More than $125,000 in Charitable Giving Fund Grants
Sparklight's Charitable Giving Fund awards over $125,000 to 28 nonprofits supporting digital literacy, food security and community programs.
-
Cemdisiran could be the first siRNA approved for the treatment of gMG and only therapy to be offered subcutaneously with four times a year dosing FDA accepted NDA under Priority Review with a target...
-
Auddia Announces LT350 Advancement Toward First AI Datacenter Deployment, Engaging Fresh Consulting to Lead Engineering and Development
-
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, June 22, 2026 (GLOBE NEWSWIRE) -- Coppernico Metals Inc. (TSX: COPR,...
-
The IRIS Phase 2 trial did not meet its primary endpoint in social communication deficits associated with ASD A prespecified analysis in adolescents with moderate to severe baseline irritability...
-
NEWTOWN, Pa., June 22, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW, Traws, the Company), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral...
-
Eledon Presents Long-Term Phase 2 BESTOW Results at ATC Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart